Company news
Novavax, Inc. news in 2022
Novavax, Inc.'s news releases, calls and decks from 2022, newest first.
Novavax to Participate in BofA Securities 2022 Healthcare Conference
May 3, 2022
Novavax to Host Conference Call to Discuss First Quarter 2022 Financial Results and Operational Highlights on May 9, 2022
May 1, 2022
Novavax Announces Initiation of COVID-19 Vaccine Booster Study in Adolescents in Phase 3 PREVENT-19 Trial
April 21, 2022
Initial Results from Novavax' COVID-19-Influenza Vaccine Trial are First to Show Feasibility of Combination Vaccine
April 19, 2022
Novavax Announces Approval of Nuvaxovid™ COVID-19 Vaccine for Primary and Booster Immunization in Japan
April 18, 2022
Novavax Grows Presence at World Vaccine Congress and 32nd European Congress of Clinical Microbiology & Infectious Diseases
April 17, 2022
Swissmedic Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine
April 12, 2022
Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax' COVID-19 Vaccine in Thailand
April 7, 2022
Novavax Submits Request to Expand Conditional Marketing Authorization of COVID-19 Vaccine in the European Union to Adolescents (Ages 12-17)
March 30, 2022
Novavax Announces Participation in Two Booster Studies Using its COVID-19 Vaccine
March 24, 2022
Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax' COVID-19 Vaccine in Adolescents ≥12 to <18 in India
March 21, 2022
Novavax Announces Launch of Global Vaccine Education Programs
March 9, 2022
Novavax to Participate in Cowen's 42nd Annual Health Care Conference
March 1, 2022
Novavax Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights
February 27, 2022
Novavax Announces Extended Durability of Protection Against Infection and Disease in United Kingdom COVID-19 Vaccine Phase 3 Clinical Trial
February 27, 2022
Novavax to Host Conference Call to Discuss Fourth Quarter and Full Year 2021 Financial Results and Operational Highlights on February 28, 2022
February 20, 2022
Health Canada Authorizes Novavax COVID-19 Vaccine
February 16, 2022
Singapore Health Sciences Authority Issues Interim Authorization for Novavax COVID-19 Vaccine
February 13, 2022
Novavax Files for Conditional Marketing Authorization of COVID-19 Vaccine in Switzerland
February 13, 2022
Novavax to Participate in Fireside Chat at the 11th Annual SVB Leerink Global Healthcare Conference
February 10, 2022
Novavax Announces Positive Results of COVID-19 Vaccine in Pediatric Population of PREVENT-19 Phase 3 Clinical Trial
February 9, 2022
New Zealand's Medsafe Grants Provisional Approval for Novavax' COVID-19 Vaccine
February 2, 2022
Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*
February 2, 2022
Novavax Submits Request to the U.S. FDA for Emergency Use Authorization of COVID-19 Vaccine
January 30, 2022
Novavax and Israel Announce Advance Purchase Agreement for Supply of COVID-19 Vaccine
January 27, 2022
Australia Therapeutic Goods Administration (TGA) Grants Provisional Registration for Novavax COVID-19 Vaccine
January 18, 2022
South Korea Ministry of Food and Drug Safety Approves Novavax COVID-19 Vaccine
January 11, 2022
Novavax and Serum Institute of India File for Emergency Use Authorization of Novavax' COVID-19 Vaccine in South Africa
January 9, 2022
Novavax to Participate in the 40th Annual J.P. Morgan Healthcare Conference
January 3, 2022
Calls in 2022
Decks in 2022
- Technical Presentation (April 2022)
Technical · 40 slides · Apr 20, 2022
- Technical Presentation (February 2022)
Technical · 18 slides · Feb 10, 2022
- Investor Presentation (January 2022)
Investor deck · 22 slides · Jan 10, 2022
- J.P. Morgan 40th Annual Healthcare Conference 2022
Conference · 22 slides · Jan 10, 2022
- J.P. Morgan 40th Annual Healthcare Conference 2022
Conference · 22 slides · January 2022